Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of September 2021. The report serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a disclosure of an insider transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of American Depositary Shares (ADSs) |
| Insider Name | Dr. H. Barron (Chief Scientific Officer and President, R&D) |
| Transaction Date | September 22, 2021 |
| Volume | 1,273.113 ADSs |
| Price per ADS | $39.28 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single acquisition event within an Executive Supplemental Savings Plan account.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory compliance document for a specific transaction.
Key Facts for Investor Verification
- Dr. H. Barron acquired 1,273.113 ADSs at $39.28 per share on September 22, 2021.
- The transaction was executed on the New York Stock Exchange.
- The purchase was made within the context of the GSK Executive Supplemental Savings Plan.
- This filing does not contain quarterly or annual financial results.